Journal
HYPERTENSION
Volume 77, Issue 5, Pages 1528-1538Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/HYPERTENSIONAHA.120.16402
Keywords
antihypertensive agents; atenolol; blood pressure; hypertension; stroke
Categories
Funding
- Bio Industrial Strategic Technology Development Program - Ministry of Trade, Industry and Energy (Korea) [20001234]
- Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health and Welfare, Republic of Korea [HI16C0992]
- Yonsei University College of Medicine [6-2019-0170]
- Korean Centers for Disease Control and Prevention [2018ER6302-01]
- Korea Evaluation Institute of Industrial Technology (KEIT) [20001234] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
The study found no significant differences in the effectiveness and safety when comparing the third-generation beta-blockers with atenolol as first-line treatment for hypertension, but patients on third-generation beta-blockers had a higher risk of stroke compared to those on ACE inhibitors and thiazide diuretics.
Evidence for the effectiveness and safety of the third-generation beta-blockers other than atenolol in hypertension remains scarce. We assessed the effectiveness and safety of beta-blockers as first-line treatment for hypertension using 3 databases in the United States: 2 administrative claims databases and 1 electronic health record-based database from 2001 to 2018. In each database, comparative effectiveness of beta-blockers for the risks of acute myocardial infarction, stroke, and hospitalization for heart failure was assessed, using large-scale propensity adjustment and empirical calibration. Estimates were combined across databases using random-effects meta-analyses. Overall, 118 133 and 267 891 patients initiated third-generation beta-blockers (carvedilol and nebivolol) or atenolol, respectively. The pooled hazard ratios (HRs) of acute myocardial infarction, stroke, hospitalization for heart failure, and most metabolic complications were not different between the third-generation beta-blockers versus atenolol after propensity score matching and empirical calibration (HR, 1.07 [95% CI, 0.74-1.55] for acute myocardial infarction; HR, 1.06 [95% CI, 0.87-1.31] for stroke; HR, 1.46 [95% CI, 0.99-2.24] for hospitalized heart failure). Third-generation beta-blockers were associated with significantly higher risk of stroke than ACE (angiotensin-converting enzyme) inhibitors (HR, 1.29 [95% CI, 1.03-1.72]) and thiazide diuretics (HR, 1.56 [95% CI, 1.17-2.20]). In conclusion, this study found many patients with first-line beta-blocker monotherapy for hypertension and no statistically significant differences in the effectiveness and safety comparing atenolol with third-generation beta-blockers. Patients on third-generation beta-blockers had a higher risk of stroke than those on ACE inhibitors and thiazide diuretics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available